Johanna Ihli, BSN
Former Registered Nurse · Independent Researcher in Drug-Induced Mitochondrial Dysfunction · Founder, druginducedmito.org
How This Work Began
This work did not begin in a laboratory or an academic institution. It began through decades of lived experience — a long and evolving pattern of health issues that often failed to fit neatly within traditional organ-based medical models.
Beginning in 2007 after Cipro exposure, a progressively disabling constellation of symptoms emerged across multiple body systems: fatigue, musculoskeletal pain, connective tissue problems, neurologic symptoms, autonomic dysfunction, and recurrent unexplained systemic decline. Over the years, these symptoms were frequently fragmented into separate diagnoses rather than understood as part of a unified process. Only later, through retrospective review, did earlier health patterns from the 1980s and 1990s appear potentially related rather than isolated or unrelated events.
"As both a patient and a healthcare professional, I experienced firsthand the gap that can exist between patient-reported patterns and the frameworks available to interpret them clinically."
After recognizing a possible connection between fluoroquinolone antibiotic exposure and the progression of these symptoms, an independent investigation began into mitochondrial biology, pharmacology, toxicology, adverse event reporting systems, and the emerging literature surrounding medication-induced mitochondrial injury.
What started as an effort to understand a personal condition gradually evolved into a broader systems-level investigation — into how modern pharmacovigilance may overlook delayed, cumulative, and multisystem medication effects.
Two Lenses on the Same Problem
This work is informed by two complementary perspectives that rarely exist in the same person:
Clinical Training
Over three decades as a registered nurse in emergency, trauma, and critical care — learning firsthand how guideline-based systems, diagnostic categories, and healthcare protocols function under real-world pressure.
Patient Experience
Nearly four decades of progressive, unexplained multisystem decline following medication exposures — navigating a fragmented healthcare system that struggled to unify what was happening across specialties.
Independent Research
Self-directed study into mitochondrial biology, pharmacotoxicology, pharmacovigilance architecture, and the emerging science of delayed drug-induced energy system injury — driven by the need to find a framework that actually fit.
This combination — clinical systems knowledge, patient-reported pattern recognition, and independent mechanistic research — is what shapes the DIMD framework. It is not one perspective alone, but the intersection of all three.
A Four-Decade Arc
The following timeline reflects a decades-long clinical trajectory that began with unexplained neurologic, cardiac, and connective-tissue symptoms and later became recognizable as part of a broader multisystem pattern. It is included not as proof of causation by itself, but because it explains how clinical experience, patient observation, and later mitochondrial research converged into the DIMD framework.
1980s
First Remembered Ciprofloxacin Exposure
First remembered exposure to ciprofloxacin occurred in the late 1980s for an ear infection.
1996
Early Voice and Cardiac Symptoms
Voice symptoms developed in the mid-1990s and were eventually diagnosed as spasmodic dysphonia around 1996. Around this same period, a significant PSVT/SVT episode occurred that required adenosine for conversion.
1998
GBS-Like Neurologic Episode
After graduating with a BSN in December 1997 and beginning emergency nursing work, lower-extremity numbness and tingling developed, beginning in the feet and gradually ascending but stopping around the knees. Symptoms progressed to stumbling and foot drop, requiring braces for ambulation. Neurologic evaluation at a major academic medical center included diagnostic workup and nerve biopsy. The best clinical impression was Guillain-Barré syndrome or a demyelination/regeneration process. Symptoms improved over several months, but the episode remained without a fully unifying explanation.
Neurologic EpisodeLeft ACL Tear
A left ACL tear occurred during the early musculoskeletal injury period and required surgical repair.
Second Ciprofloxacin Exposure and Left Achilles/Gastrocnemius Injury
In 2007, after taking a single oral dose of ciprofloxacin, I suffered a spontaneous rupture of the left Achilles tendon/gastrocnemius complex. The injury occurred within approximately 24 hours of exposure and in the absence of any significant traumatic event. The rupture was severe enough to require prolonged immobilization and marked the beginning of a cascade of subsequent musculoskeletal complications.
Exposure EventRight Achilles/Gastrocnemius Injury
A similar right-sided Achilles/gastrocnemius injury occurred the following year while transferring a patient in the ICU.
2009
Progressive Tendon and Connective-Tissue Injury
Following the bilateral lower-leg tendon injuries, additional musculoskeletal problems developed — including left hip labral, ligament, and tendon involvement after altered gait and boot use — along with worsening back, SI, and hip pain, and recurrent tendon and connective-tissue symptoms. Because the fluoroquinolone-associated pattern was not recognized at the time, treatment continued through conventional musculoskeletal pathways, including repeated hip injections, a lumbar epidural, NSAIDs, and corticosteroid exposure — interventions now commonly cautioned against in FQAD contexts due to their potential to worsen symptoms.
Hysterectomy and Pelvic Disease
A total hysterectomy was performed after severe pelvic and back pain had been attributed to endometriosis. Operative findings included severe endometriosis and polycystic ovaries despite no prior history of PCOS. During recovery from anesthesia, there was difficulty reversing or awakening from surgery, and the anesthesiologist was present at bedside when I woke. In retrospect, this perioperative event became another data point in the broader pattern of medication sensitivity and possible mitochondrial vulnerability.
2012
Disability and Loss of Clinical Career
Multisystem symptoms progressed, including worsening pain, fatigue, neurologic symptoms, autonomic and cardiac symptoms, medication sensitivity, and recurrent musculoskeletal problems. By approximately 2010, nursing work was no longer sustainable, and by 2012 permanent disability had been established.
Career End2019
Chronic Unexplained Multisystem Illness
Persistent symptoms continued without a unifying diagnosis — including neuropathic pain, vibration sensations, tendon and ligament pain, sleep disruption, medication sensitivity, temperature and autonomic symptoms, and post-exertional worsening. Later symptom logs documented the persistence and fluctuation of this pattern.
Recurrent Tendon Flares
Recurrent tendon, adductor, hamstring, and groin pain continued, along with difficulty walking, edema around the left ankle, calf, and thigh, Baker's cyst history, and persistent tendon-related limitations.
Delayed Recognition of Longstanding Neuropathic Symptoms
Right upper-thigh symptoms that had been present for years were formally diagnosed as meralgia paresthetica in 2023 — illustrating the long delay between symptom onset and clinical labeling that is characteristic of this type of multisystem pattern.
Recognition of a Possible DIMD/FQAD Framework
The long clinical pattern began to be reconsidered through the lens of fluoroquinolone-associated disability and drug-induced mitochondrial dysfunction. This was not a pre-formed theory; it emerged after years of documented symptoms, fragmented evaluations, and later research into mitochondrial biology and fluoroquinolone mechanisms.
Framework RecognitionObjective Mitochondrial Finding
MitoSwab testing showed severe isolated Complex I deficiency in buccal cells. This objective mitochondrial finding became an important biological anchor for re-examining the prior decades-long clinical trajectory through the lens of DIMD/FQAD.
Complex I Deficiency · Objective FindingResearch, Registry, and Advocacy Phase
The personal clinical trajectory became part of a broader research and advocacy effort focused on delayed multisystem drug injury, mitochondrial vulnerability, patient-reported outcomes, and gaps in pharmacovigilance. This work now includes the DIMD Registry, FDA Citizen Petition activity (Docket FDA-2026-P-5116), website development, and public education around mitochondrial safety.
FDA Petition · Registry · AdvocacyThe importance of this history is not that one patient's experience proves a mechanism. It is that the pattern — delayed onset, multisystem involvement, fragmented specialty evaluation, recurrent tendon and neurologic symptoms, and eventual objective mitochondrial abnormality — reflects the type of clinical trajectory current pharmacovigilance systems are not designed to capture well. Yet this pattern now exists in the space between regulatory recognition, ICD-10-CM coding capacity, and clinical education: adverse-effect codes may exist, but clinicians have not been broadly trained to recognize the delayed multisystem pattern those codes are meant to document.
What This Initiative Is Building
Today, the focus is on increasing awareness of mitochondrial vulnerability in medicine, improving informed consent and pharmacovigilance frameworks, and advancing recognition of DIMD as a potentially underrecognized contributor to chronic multisystem illness.
This is not a single-discipline effort. It sits at the intersection of molecular biology, clinical medicine, patient experience, and regulatory policy — and it requires all four lenses to do the work properly.
- druginducedmito.org — educational and advocacy initiative for public awareness, research communication, and patient support
- FDA Citizen Petition — Docket FDA-2026-P-5116, requesting stronger informed-consent and risk communication for fluoroquinolone antibiotics
- Manuscript submitted for journal consideration — advancing the mechanistic and pharmacovigilance framework
- DIMD Registry — structured patient data collection to build the longitudinal evidence base
- Clinician & policymaker education — bridging the gap between what molecular science understands and what clinical practice currently reflects
"The limitation lies not in the absence of signal — but in the framework used to interpret it. If our understanding of energy biology has advanced, shouldn't our safety models evolve with it?"
— Core framing, DIMD InitiativeCredentials
Johanna Ihli, BSN
Former Registered Nurse
Emergency · Trauma · Critical Care
Independent Researcher
Drug-Induced Mitochondrial Dysfunction
Founder, druginducedmito.org
ORCID: 0009-0008-1486-7242This site is for educational and advocacy purposes only. It does not provide medical advice, and nothing here should be interpreted as a clinical recommendation or treatment guidance.
The Work Continues
Whether you are a patient, clinician, researcher, or policymaker — there is a place for you in this effort. Help build the evidence base that has been missing.